GSK

The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.